Hello and welcome to The Friday Kable, where we continue to hate on sugar substitutes, Indian pharma manufacturers continue to mess up, and semaglutide continues to prove its appeal.
But first, some Big Pharma updates. Eli Lilly is acquiring the cell therapy developer Sigilon Therapeutics for an upfront payment of a little under $35 million. The two comp…